NASDAQ:AVIR Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free AVIR Stock Alerts $3.70 -0.01 (-0.27%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$3.66▼$3.7450-Day Range$3.67▼$4.1052-Week Range$2.77▼$5.19Volume523,247 shsAverage Volume397,475 shsMarket Capitalization$311.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Atea Pharmaceuticals alerts: Email Address Atea Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish2.43% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.76) to ($2.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.49 out of 5 starsMedical Sector885th out of 929 stocksPharmaceutical Preparations Industry415th out of 433 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Atea Pharmaceuticals.Read more about Atea Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.43% of the float of Atea Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAtea Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Atea Pharmaceuticals has recently increased by 2.86%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAtea Pharmaceuticals does not currently pay a dividend.Dividend GrowthAtea Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVIR. Previous Next 2.4 News and Social Media Coverage News SentimentAtea Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Atea Pharmaceuticals this week, compared to 1 article on an average week.Search Interest2 people have searched for AVIR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atea Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders14.50% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atea Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Atea Pharmaceuticals are expected to decrease in the coming year, from ($2.76) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atea Pharmaceuticals is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atea Pharmaceuticals is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtea Pharmaceuticals has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Atea Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhat’s Really Next for America…Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly.Click here to stream this controversial exposé now. About Atea Pharmaceuticals Stock (NASDAQ:AVIR)Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Read More AVIR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVIR Stock News HeadlinesMay 16 at 9:01 AM | markets.businessinsider.comAtea Pharmaceuticals: Assessing Bemnifosbuvir’s Prospects Amidst Clinical and Financial ChallengesMay 16 at 4:01 AM | investing.comAtea Pharmaceuticals Inc (AVIR)May 15 at 9:09 AM | msn.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2024 Earnings Call TranscriptMay 15 at 9:09 AM | finance.yahoo.comAtea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...May 14 at 9:04 PM | investorplace.comAVIR Stock Earnings: Atea Pharmaceuticals Misses EPS for Q1 2024May 14 at 6:07 PM | msn.comAtea Pharmaceuticals GAAP EPS of -$0.75 misses by $0.14May 14 at 6:07 PM | finance.yahoo.comAtea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 12, 2024 | americanbankingnews.comAtea Pharmaceuticals (AVIR) to Release Earnings on TuesdayMay 7, 2024 | finance.yahoo.comAtea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024April 29, 2024 | finanznachrichten.deAtea Pharmaceuticals, Inc.: Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024April 29, 2024 | globenewswire.comAtea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024March 27, 2024 | globenewswire.comAtea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsMarch 21, 2024 | edition.cnn.comAtea Pharmaceuticals, Inc.March 16, 2024 | finance.yahoo.comAVIR Apr 2024 2.500 callMarch 3, 2024 | finance.yahoo.comAVIR Mar 2024 7.500 callMarch 1, 2024 | markets.businessinsider.comAtea Pharmaceuticals: Balancing Promising Prospects with Clinical and Regulatory RisksMarch 1, 2024 | finanznachrichten.deAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 29, 2024 | finance.yahoo.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | benzinga.comRecap: Atea Pharmaceuticals Q4 EarningsFebruary 28, 2024 | finance.yahoo.comAtea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial ResultsFebruary 28, 2024 | globenewswire.comAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 21, 2024 | finance.yahoo.comAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024February 21, 2024 | globenewswire.comAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024February 13, 2024 | stockhouse.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Atea Pharmaceuticals, Inc. (AVIR) and Encourages Investors to Contact the FirmJanuary 10, 2024 | finance.yahoo.comAtea Pharma (AVIR) Gains on Upbeat Initial Data From HCV StudySee More Headlines Receive AVIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/16/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AVIR CUSIPN/A CIK1593899 Webwww.ateapharma.com Phone857-284-8891FaxN/AEmployees75Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.07% Return on Assets-22.04% Debt Debt-to-Equity RatioN/A Current Ratio18.24 Quick Ratio18.24 Sales & Book Value Annual Sales$351.37 million Price / Sales0.89 Cash FlowN/A Price / Cash FlowN/A Book Value$6.65 per share Price / Book0.56Miscellaneous Outstanding Shares84,223,000Free Float72,011,000Market Cap$311.63 million OptionableOptionable Beta0.19 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Jean-Pierre Sommadossi Ph.D. (Age 68)Founder, Chairman, CEO & President Comp: $1.1MMs. Andrea J. Corcoran J.D. (Age 62)CFO, Executive VP of Legal & Secretary Comp: $732.45kMr. John F. Vavricka (Age 60)Chief Commercial Officer Comp: $581.11kDr. Janet M. J. Hammond M.D. (Age 63)Ph.D., Chief Development Officer Comp: $817.16kDr. Maria Arantxa Horga M.D. (Age 55)Chief Medical Officer Comp: $695.85kMr. Wayne Foster CPA (Age 55)Executive VP of Finance & Chief Accounting Officer Ms. Jonae R. BarnesSenior Vice President of Investor Relations & Corporate CommunicationsMr. Ariyapadi N. KrishnarajVice President of MarketingMr. Adel Moussa Ph.D.Executive Vice President of ChemistryMr. Xiao-Jian Zhou Ph.D.Executive Vice President of Early Stage DevelopmentMore ExecutivesKey CompetitorsVerastemNASDAQ:VSTMADC TherapeuticsNYSE:ADCTPrecigenNASDAQ:PGENKamadaNASDAQ:KMDANkartaNASDAQ:NKTXView All CompetitorsInsiders & InstitutionsTidal Investments LLCBought 21,472 shares on 5/17/2024Ownership: 0.025%Jacobs Levy Equity Management Inc.Bought 122,447 shares on 5/16/2024Ownership: 0.799%California State Teachers Retirement SystemSold 4,911 shares on 5/16/2024Ownership: 0.009%Price T Rowe Associates Inc. MDBought 11,968 shares on 5/15/2024Ownership: 0.080%Public Employees Retirement System of OhioBought 43,021 shares on 5/15/2024Ownership: 0.072%View All Insider TransactionsView All Institutional Transactions AVIR Stock Analysis - Frequently Asked Questions Should I buy or sell Atea Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atea Pharmaceuticals in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" AVIR shares. View AVIR analyst ratings or view top-rated stocks. How have AVIR shares performed in 2024? Atea Pharmaceuticals' stock was trading at $3.05 at the beginning of the year. Since then, AVIR shares have increased by 21.3% and is now trading at $3.70. View the best growth stocks for 2024 here. When is Atea Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our AVIR earnings forecast. How were Atea Pharmaceuticals' earnings last quarter? Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) posted its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.03. What ETF holds Atea Pharmaceuticals' stock? Amplify Treatments, Testing and Advancements ETF holds 19,683 shares of AVIR stock, representing 0.78% of its portfolio. When did Atea Pharmaceuticals IPO? Atea Pharmaceuticals (AVIR) raised $253 million in an IPO on Friday, October 30th 2020. The company issued 11,000,000 shares at $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair acted as the underwriters for the IPO. Who are Atea Pharmaceuticals' major shareholders? Atea Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BML Capital Management LLC (6.58%), Vanguard Group Inc. (5.61%), Jacobs Levy Equity Management Inc. (0.80%), Price T Rowe Associates Inc. MD (0.08%), Public Employees Retirement System of Ohio (0.07%) and Mirae Asset Global Investments Co. Ltd. (0.04%). Insiders that own company stock include Andrea Corcoran, Franklin M Berger, Jean-Pierre Sommadossi, Polly A Murphy and Wayne Foster. View institutional ownership trends. How do I buy shares of Atea Pharmaceuticals? Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVIR) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsObama’s Forever Term [exposed]Porter & CompanyGold Set to EXPLODE!Gold Safe ExchangeThe 1,000X Crypto PlaybookTrue Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
